Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

639 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant.
Nakamura R, La Rosa C, Yang D, Hill JA, Rashidi A, Choe H, Zhou Q, Lingaraju CR, Kaltcheva T, Longmate J, Drake J, Slape C, Duarte L, Al Malki MM, Pullarkat VA, Aribi A, Devine S, Verneris MR, Miller JS, Forman SJ, Aldoss I, Diamond DJ. Nakamura R, et al. Among authors: rashidi a. Haematologica. 2024 Feb 8. doi: 10.3324/haematol.2023.284544. Online ahead of print. Haematologica. 2024. PMID: 38328852 Free article.
A Multicenter Phase 2 Clinical Trial of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell Transplantation.
Rashidi A, Huselton EJ, Stefanski HE, DeFor TE, Shanley R, Choi J, DiPersio JF, Juckett M, Miller JS, Weisdorf DJ, Schroeder MA. Rashidi A, et al. Transplant Cell Ther. 2023 May;29(5):328.e1-328.e6. doi: 10.1016/j.jtct.2023.02.010. Epub 2023 Feb 19. Transplant Cell Ther. 2023. PMID: 36804933 Free PMC article. Clinical Trial.
Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease.
Holtan SG, Hoeschen A, Cao Q, Ustun C, Betts BC, Jurdi NE, Maakaron J, Rashidi A, Miller JS, Wagner JE, Blazar BR, Jacobson PA, Panoskaltsis-Mortari A, Weisdorf DJ, MacMillan ML. Holtan SG, et al. Among authors: rashidi a. Transplant Cell Ther. 2023 Aug;29(8):509.e1-509.e8. doi: 10.1016/j.jtct.2023.05.021. Epub 2023 Jun 4. Transplant Cell Ther. 2023. PMID: 37279855 Free PMC article. Clinical Trial.
Amphiregulin as a biomarker for monitoring lifethreatening acute graft-versus-host disease: secondary analysis of two prospective clinical trials.
Holtan SG, El Jurdi N, Rashidi A, Betts BC, Demorest C, Galvin JP, MacMillan ML, Weisdorf DJ, Panoskaltsis-Mortari A, Pratta MA. Holtan SG, et al. Among authors: rashidi a. Haematologica. 2024 May 1;109(5):1557-1561. doi: 10.3324/haematol.2023.283215. Haematologica. 2024. PMID: 37706330 Free PMC article. No abstract available.
Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate.
El Jurdi N, Hoover A, O'Leary D, Cao Q, Gupta A, Ebens C, Maakaron J, Betts BC, Rashidi A, Juckett M, Lund T, Bachanova V, MacMillan M, Miller J, Orchard P, Wagner J, Vercellotti G, Weisdorf D, Dusenbery K, Terezakis S, Holtan S. El Jurdi N, et al. Among authors: rashidi a. medRxiv [Preprint]. 2023 Mar 29:2023.03.24.23287521. doi: 10.1101/2023.03.24.23287521. medRxiv. 2023. PMID: 37034603 Free PMC article. Preprint.
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Jurdi NE, Hoover A, O'Leary D, Cao Q, Gupta A, Ebens C, Maakaron JE, Betts BC, Rashidi A, Juckett MB, Lund T, Bachanova V, MacMillan ML, Miller JS, Orchard PJ, Wagner JE, Vercellotti G, Weisdorf DJ, Dusenbery K, Terezakis S, Holtan SG. Jurdi NE, et al. Among authors: rashidi a. Transplant Cell Ther. 2023 Sep;29(9):576.e1-576.e5. doi: 10.1016/j.jtct.2023.06.008. Epub 2023 Jun 11. Transplant Cell Ther. 2023. PMID: 37311510 Clinical Trial.
Multi-omics analysis of a fecal microbiota transplantation trial identifies novel aspects of acute graft-versus-host disease pathogenesis.
Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Kazadi D, Halaweish H, Khan MH, Hoeschen A, Cao Q, Luo X, Kabage AJ, Lopez S, Ramamoorthy S, Holtan SG, Weisdorf DJ, Khoruts A, Staley C. Rashidi A, et al. Cancer Res Commun. 2024 May 20. doi: 10.1158/2767-9764.CRC-24-0138. Online ahead of print. Cancer Res Commun. 2024. PMID: 38767452 Free article.
639 results